Drugs / Adoptive Immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02757391 | Aug 2019 → Oct 2020 | carcinoma of esophagus, cholangiocarcinoma, colorectal adenocarcinoma, gastric carcinoma +1 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adoptive Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02757391 ↗ |
| Modality | Cell therapy | “personalized adoptive T cell therapy” NCT02757391 ↗ |
| Route | Intravenous | “CD8+ T cell infusion IV over 2 hours on day 0” NCT02757391 ↗ |